TheraSphere
BOSTON SCIENTIFIC CORPORATION · Decision date Feb 10, 2026
What did the FDA approve?
FDA records P200029/S011 as a supplement to PMA P200029, with the supplement type “Panel Track”. The recorded decision is approval, dated Feb 10, 2026.
FDA approval order statement
TheraSphere are indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Radiology
- Decision date
- Feb 10, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P200029/S011
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- NAW
- Decision code
- APPR
- Decision date
- Feb 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Microspheres radionuclide.
- Applicant
- Boston Scientific Corporation
- Product code
- NAW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200029 · Original PMA
TheraSphere
P200029/S011 received
Application receipt date recorded by FDA.
P200029/S011 · FDA decision
Panel Track
P200029/S012 · Related supplement
TheraSphere
P200029/S013 · Related supplement
TheraSphere Y-90 Glass Microspheres System
P200029/S014 · Related supplement
TheraSphere
P200029/S015 · Related supplement
TheraSphere Y-90 Glass Microspheres System
Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TheraSphereP200029 | BOSTON SCIENTIFIC CORPORATION | PMA approval | Mar 17, 2021 | FDA |
TheraSphereP200029/S012 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Apr 10, 2026 | FDA |
TheraSphere Y-90 Glass Microspheres SystemP200029/S013 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jun 4, 2026 | FDA |
TheraSphereP200029/S014 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
TheraSphere Y-90 Glass Microspheres SystemP200029/S015 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 13, 2026 | FDA |
Explore the linked device profile
Other records with product code NAW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SIR-Spheres Y-90 resin microspheresP990065/S019 | Sirtex Medical, Inc. | PMA supplement | May 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 300 Boston Scientific Way, Marborough, MA, 01752
Sources and methodology
- Original FDA record: P200029/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



